Fresenius Medical Care AG (NYSE:FMS) Receives $24.30 Average Price Target from Brokerages

Shares of Fresenius Medical Care AG (NYSE:FMS) have received an average rating of “Hold” from the five research firms that are currently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $24.30.

FMS has been the topic of a number of analyst reports. StockNews.com initiated coverage on shares of Fresenius Medical Care in a report on Friday, November 1st. They set a “strong-buy” rating on the stock. Berenberg Bank initiated coverage on shares of Fresenius Medical Care in a report on Wednesday. They set a “buy” rating and a $25.60 target price on the stock. Finally, Truist Financial boosted their target price on shares of Fresenius Medical Care from $22.00 to $23.00 and gave the company a “hold” rating in a report on Monday, October 7th.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Creative Planning increased its holdings in shares of Fresenius Medical Care by 18.9% in the second quarter. Creative Planning now owns 40,140 shares of the company’s stock worth $766,000 after purchasing an additional 6,373 shares during the period. Wulff Hansen & CO. grew its position in Fresenius Medical Care by 1,809.0% in the second quarter. Wulff Hansen & CO. now owns 343,429 shares of the company’s stock worth $6,556,000 after acquiring an additional 325,439 shares in the last quarter. QRG Capital Management Inc. grew its position in Fresenius Medical Care by 19.5% in the first quarter. QRG Capital Management Inc. now owns 54,363 shares of the company’s stock worth $1,048,000 after acquiring an additional 8,870 shares in the last quarter. SG Americas Securities LLC grew its position in Fresenius Medical Care by 50.0% in the first quarter. SG Americas Securities LLC now owns 15,228 shares of the company’s stock worth $294,000 after acquiring an additional 5,078 shares in the last quarter. Finally, Marshall Wace LLP grew its position in Fresenius Medical Care by 8.5% in the second quarter. Marshall Wace LLP now owns 15,363 shares of the company’s stock worth $293,000 after acquiring an additional 1,207 shares in the last quarter. Institutional investors own 8.25% of the company’s stock.

Fresenius Medical Care Price Performance

Fresenius Medical Care stock opened at $21.29 on Wednesday. Fresenius Medical Care has a 12 month low of $16.86 and a 12 month high of $22.76. The company has a current ratio of 1.46, a quick ratio of 1.09 and a debt-to-equity ratio of 0.45. The business’s 50 day simple moving average is $20.46 and its 200 day simple moving average is $20.23. The company has a market cap of $12.49 billion, a price-to-earnings ratio of 21.94, a PEG ratio of 0.97 and a beta of 0.91.

Fresenius Medical Care Company Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.